1. Anon (2001). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. S7A: Safety Pharmacology Studies for Human Pharmaceuticals (ICH S7A).
2. S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals (S7B);Anon;Federal Register,2005
3. Origins, practices and future of safety pharmacology;Bass;Journal of Pharmacological and Toxicological Methods,2004
4. Introduction to Nonclinical safety pharmacology and the safety pharmacology society;Bass;Journal of Pharmacological and Toxicological Methods,2004
5. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity;Bertaina-Anglade;Journal of Pharmacological and Toxicological Methods,2006